PSVD without portal hypertension - Paris PSVD Meeting

Value of the Information & Strength of the Argument

The talk provides valuable insights into the natural history of PSVD without portal hypertension, a poorly understood condition. The speaker presents preliminary data from a multicenter study, which adds to the limited existing literature. The argumentation is logical, starting with illustrative cases, reviewing current definitions, and then presenting new data. He acknowledges limitations, such as selection bias and the need for central review of biopsies. The discussion with the audience adds depth, addressing practical questions about diagnosis and follow-up. However, the data are preliminary and not yet peer-reviewed, and some conclusions are based on small numbers.

Scientific Rigor, Source Quality, Title Accuracy

The speaker references the VALDIG study and another study (likely the one by Cazals-Hatem et al.) but does not provide specific citations or URLs. The talk is based on expert opinion and preliminary data, not a systematic review. The title accurately reflects the content. The video description includes links to the organizing networks (EURO-VALDI-NET and FILFOIE) and their social media, but no direct references to scientific papers. The speaker does not explicitly cite sources during the talk, which limits the ability to verify claims. However, the context of a scientific meeting suggests a high level of expertise.

The title accurately reflects the content, which focuses on PSVD without portal hypertension.

7/10

Presentation by a recognized expert at an international scientific meeting, based on preliminary data from a multicenter study and a review of existing literature. However, the data are preliminary and not yet peer-reviewed, and the talk includes personal opinions and interpretations.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and presentation of two cases illustrating PSVD heterogeneity
• 03:00Discussion of current definition of PSVD and the issue of diagnosing without portal hypertension
• 06:00Review of available studies on PSVD without portal hypertension
• 09:00Presentation of preliminary results from the VALDIG study
• 12:00Comparison with another study and discussion of differences
• 15:00Conclusions and clinical implications
• 18:00Q&A session with audience questions

• VALDIG study (preliminary data) — Mentioned as a retrospective multicenter study including patients without portal hypertension
• Study by Cazals-Hatem et al. (likely) — Referred to as 'the other study' with 59 patients with obliterative portal venopathy

• Cazals-Hatem D, et al. Obliterative portal venopathy: a study of 59 patients. J Hepatol. 2014. — The study mentioned in the talk, showing similar findings of low incidence of portal hypertension in patients without it at diagnosis.

• Potential selection bias in tertiary center studies — The speaker acknowledges that studies from tertiary centers may overrepresent severe cases, potentially affecting the generalizability of the findings.